Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TEVA logo TEVA
Upturn stock ratingUpturn stock rating
TEVA logo

Teva Pharma Industries Ltd ADR (TEVA)

Upturn stock ratingUpturn stock rating
$18.04
Last Close (24-hour delay)
Profit since last BUY-0.11%
upturn advisory
Consider higher Upturn Star rating
BUY since 9 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: TEVA (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

11 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $23.56

1 Year Target Price $23.56

Analysts Price Target For last 52 week
$23.56 Target price
52w Low $12.47
Current$18.04
52w High $22.8

Analysis of Past Performance

Type Stock
Historic Profit 24.42%
Avg. Invested days 58
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 20.76B USD
Price to earnings Ratio -
1Y Target Price 23.56
Price to earnings Ratio -
1Y Target Price 23.56
Volume (30-day avg) 11
Beta 0.62
52 Weeks Range 12.47 - 22.80
Updated Date 08/28/2025
52 Weeks Range 12.47 - 22.80
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.15

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-30
When -
Estimate 0.63
Actual 0.66

Profitability

Profit Margin -0.94%
Operating Margin (TTM) 21.41%

Management Effectiveness

Return on Assets (TTM) 5.37%
Return on Equity (TTM) -2.42%

Valuation

Trailing PE -
Forward PE 6.95
Enterprise Value 36044131084
Price to Sales(TTM) 1.25
Enterprise Value 36044131084
Price to Sales(TTM) 1.25
Enterprise Value to Revenue 2.17
Enterprise Value to EBITDA 19.02
Shares Outstanding 1147149952
Shares Floating 1141529878
Shares Outstanding 1147149952
Shares Floating 1141529878
Percent Insiders -
Percent Institutions 66.14

ai summary icon Upturn AI SWOT

Teva Pharma Industries Ltd ADR

stock logo

Company Overview

overview logo History and Background

Teva Pharmaceutical Industries Ltd. was founded in 1901 in Jerusalem. Initially a small wholesaler, it evolved into a global pharmaceutical company through organic growth and strategic acquisitions, focusing on generic and specialty medicines.

business area logo Core Business Areas

  • Generic Medicines: Teva is a leading generic pharmaceutical manufacturer, producing a wide range of generic drugs across various therapeutic areas.
  • Specialty Medicines: Teva develops and markets specialty medicines, focusing on central nervous system (CNS) disorders, pain, and respiratory diseases.
  • Biopharmaceuticals: Teva has a growing biopharmaceutical business, developing biosimilars and innovative biologics.

leadership logo Leadership and Structure

Teva is led by a CEO and a board of directors. The organizational structure includes global functions such as R&D, operations, and commercial operations, along with regional business units.

Top Products and Market Share

overview logo Key Offerings

  • Copaxone: A specialty medicine for multiple sclerosis (MS). While patent protection has expired, it remains a significant revenue contributor. Competitors include Biogen (Tecfidera), Novartis (Gilenya), and Roche (Ocrevus).
  • Generic Medicines Portfolio: Teva has a broad portfolio of generic drugs, including generics for high-demand medications across multiple therapeutic areas. Competitors include Mylan (Viatris), Sandoz (Novartis), and Sun Pharmaceutical.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The generic drug market is driven by patent expirations and cost-containment pressures, while the specialty drug market is focused on innovative therapies for unmet medical needs.

Positioning

Teva is a leading generic pharmaceutical company with a strong presence in specialty medicines. Its competitive advantage lies in its broad product portfolio, global manufacturing network, and expertise in generic drug development.

Total Addressable Market (TAM)

The global pharmaceuticals market is estimated at over $1 trillion. Teva targets both the generic and specialty segments. Its TAM is significant, with positioning focused on affordability and access through generics, and innovation in specialty areas.

Upturn SWOT Analysis

Strengths

  • Global Manufacturing and Distribution Network
  • Extensive Portfolio of Generic Drugs
  • Established Presence in Specialty Medicines
  • Strong R&D Capabilities in Generics

Weaknesses

  • High Debt Levels
  • Loss of Exclusivity on Key Products (e.g., Copaxone)
  • Exposure to Pricing Pressure in the Generic Market
  • Litigation and Regulatory Risks

Opportunities

  • Growth in Emerging Markets
  • Development of Biosimilars
  • Strategic Partnerships and Acquisitions
  • Expansion of Specialty Medicines Portfolio

Threats

  • Increased Competition from Generic Manufacturers
  • Patent Challenges and Litigation
  • Pricing Regulations and Reimbursement Pressures
  • Economic Downturns Impacting Healthcare Spending

Competitors and Market Share

competitor logo Key Competitors

  • VTRS
  • NVS
  • SUN

Competitive Landscape

Teva faces stiff competition in both the generic and specialty pharmaceutical markets. It is focusing on cost efficiencies and strategic partnerships to maintain its competitive position. Teva has an advantage in generics due to its wide portfolio, but it faces pricing pressure. Teva's focus on debt reduction will allow it to invest more in innovation and strategic growth.

Major Acquisitions

Actavis Generics

  • Year: 2016
  • Acquisition Price (USD millions): 40500
  • Strategic Rationale: Acquired Actavis Generics to expand its generic drug portfolio and global reach, however, the size of this acquisition has contributed to Teva's high debt

Growth Trajectory and Initiatives

Historical Growth: Teva's growth has been challenged in recent years due to generic pricing pressure and loss of exclusivity on key products.

Future Projections: Analyst estimates vary, but projections generally anticipate modest revenue growth driven by new product launches and expansion in emerging markets. Profitability improvements are expected as debt is reduced.

Recent Initiatives: Teva is focused on debt reduction, streamlining operations, and investing in its pipeline of specialty and biosimilar products.

Summary

Teva faces challenges stemming from its high debt load and generic pricing pressures. However, it maintains a strong position in the generic market with a vast portfolio and global distribution network. Strategic focus on debt reduction and specialty medicines may provide a path to sustained growth. Investors should watch for improvements in profitability and pipeline development as key indicators.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (10K, 10Q), Analyst reports, Market research reports

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Teva Pharma Industries Ltd ADR

Exchange NYSE
Headquaters -
IPO Launch date 1990-03-26
President, CEO & Director Mr. Richard D. Francis
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 37000
Full time employees 37000

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.